Literature DB >> 6416560

Luteinising hormone releasing hormone agonist in women with endometriosis.

D W Pring, M Maresh, A C Fraser, S Lightman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6416560      PMCID： PMC1550118          DOI： 10.1136/bmj.287.6406.1718-c

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Danazol treatment of endometriosis: long-term follow-up.

Authors:  R B Greenblatt; V Tzingounis
Journal:  Fertil Steril       Date:  1979-11       Impact factor: 7.329

2.  Antigonadotropin (danazol) in the treatment of endometriosis. Evaluation of posttreatment fertility and three-year follow-up data.

Authors:  W P Dmowski; M R Cohen
Journal:  Am J Obstet Gynecol       Date:  1978-01-01       Impact factor: 8.661

3.  "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.

Authors:  D R Meldrum; R J Chang; J Lu; W Vale; J Rivier; H L Judd
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958
  3 in total
  3 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 3.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.